118 related articles for article (PubMed ID: 26060680)
1. Effect of PTEN Gene Mutations and Environmental Risk Factors on the Progression and Prognosis of Bladder Cancer.
Mashhadi R; Pourmand G; Mehrsai A; Pakdel S; Dialameh H; Ahmadi A; Salem S; Salimi E; Mahboubi R
Iran J Public Health; 2014 Jan; 43(1):56-61. PubMed ID: 26060680
[TBL] [Abstract][Full Text] [Related]
2. Point mutation and homozygous deletion of PTEN/MMAC1 in primary bladder cancers.
Cairns P; Evron E; Okami K; Halachmi N; Esteller M; Herman JG; Bose S; Wang SI; Parsons R; Sidransky D
Oncogene; 1998 Jun; 16(24):3215-8. PubMed ID: 9671402
[TBL] [Abstract][Full Text] [Related]
3. Molecular alterations associated with bladder cancer initiation and progression.
Cordon-Cardo C
Scand J Urol Nephrol Suppl; 2008 Sep; (218):154-65. PubMed ID: 18815930
[TBL] [Abstract][Full Text] [Related]
4. Clinical value of PTEN in patients with superficial bladder cancer.
Han KS; Jeong IG; Joung JY; Yang SO; Chung J; Seo HK; Kwon KS; Park WS; Lee KH
Urol Int; 2008; 80(3):264-9. PubMed ID: 18480628
[TBL] [Abstract][Full Text] [Related]
5. PI3K/AKT pathway activation in bladder carcinogenesis.
Calderaro J; Rebouissou S; de Koning L; Masmoudi A; Hérault A; Dubois T; Maille P; Soyeux P; Sibony M; de la Taille A; Vordos D; Lebret T; Radvanyi F; Allory Y
Int J Cancer; 2014 Apr; 134(8):1776-84. PubMed ID: 24122582
[TBL] [Abstract][Full Text] [Related]
6. PTEN deletions are related to disease progression and unfavourable prognosis in early bladder cancer.
Cordes I; Kluth M; Zygis D; Rink M; Chun F; Eichelberg C; Dahlem R; Fisch M; Höppner W; Wagner W; Doh O; Terracciano L; Simon R; Wilczak W; Sauter G; Minner S
Histopathology; 2013 Nov; 63(5):670-7. PubMed ID: 24004025
[TBL] [Abstract][Full Text] [Related]
7. Mutations in the PTEN tumor gene and risk of endometriosis: a case-control study.
Govatati S; Kodati VL; Deenadayal M; Chakravarty B; Shivaji S; Bhanoori M
Hum Reprod; 2014 Feb; 29(2):324-36. PubMed ID: 24154570
[TBL] [Abstract][Full Text] [Related]
8. p53 Gene mutations in superficial bladder cancer.
Lorenzo Romero JG; Salinas Sánchez AS; Giménez Bachs JM; Sánchez Sánchez F; Escribano Martínez J; Hernández Millán IR; Segura Martín M; Virseda Rodríguez JA
Urol Int; 2004; 73(3):212-8. PubMed ID: 15539839
[TBL] [Abstract][Full Text] [Related]
9. [Molecular changes in development and progression of urothelial carcinoma].
Hartmann A
Verh Dtsch Ges Pathol; 2003; 87():172-84. PubMed ID: 16888910
[TBL] [Abstract][Full Text] [Related]
10. [The diagnostic value of microsatellite LOH analysis and the prognostic relevance of angiogenic gene expression in urinary bladder cancer].
Szarvas T
Magy Onkol; 2009 Dec; 53(4):385-9. PubMed ID: 20071311
[TBL] [Abstract][Full Text] [Related]
11. Mutational and expressional analyses of PTEN gene in colorectal cancer from Northern India.
Ali A; Saluja SS; Hajela K; Mishra PK; Rizvi MA
Mol Carcinog; 2014 Feb; 53 Suppl 1():E45-52. PubMed ID: 23359334
[TBL] [Abstract][Full Text] [Related]
12. Molecular pathways of urothelial development and bladder tumorigenesis.
Castillo-Martin M; Domingo-Domenech J; Karni-Schmidt O; Matos T; Cordon-Cardo C
Urol Oncol; 2010; 28(4):401-8. PubMed ID: 20610278
[TBL] [Abstract][Full Text] [Related]
13. No mutations of FGFR3 in normal urothelium in the vicinity of urothelial carcinoma of the bladder harbouring activating FGFR3 mutations in patients with bladder cancer.
Otto W; Denzinger S; Bertz S; Gaumann A; Wild PJ; Hartmann A; Stoehr R
Int J Cancer; 2009 Nov; 125(9):2205-8. PubMed ID: 19621447
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of non-muscle-invasive bladder tumor history in patients with upper urinary tract urothelial carcinoma.
Milojevic B; Djokic M; Sipetic-Grujicic S; Grozdic Milojevic I; Vuksanovic A; Nikic P; Vukovic I; Djordjevic D; Bumbasirevic U; Tulic C
Urol Oncol; 2013 Nov; 31(8):1615-20. PubMed ID: 22521771
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 in voided urine samples from patients with transitional cell carcinoma of the bladder.
Durkan GC; Nutt JE; Rajjayabun PH; Neal DE; Lunec J; Mellon JK
Clin Cancer Res; 2001 Nov; 7(11):3450-6. PubMed ID: 11705862
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of molecular markers, sub-stage and European Organisation for the Research and Treatment of Cancer risk scores in primary T1 bladder cancer.
van Rhijn BW; Liu L; Vis AN; Bostrom PJ; Zuiverloon TC; Fleshner NE; van der Aa MN; Alkhateeb SS; Bangma CH; Jewett MA; Zwarthoff EC; Bapat B; van der Kwast TH; Zlotta AR
BJU Int; 2012 Oct; 110(8):1169-76. PubMed ID: 22448597
[TBL] [Abstract][Full Text] [Related]
17. Somatic mutation of PTEN in bladder carcinoma.
Aveyard JS; Skilleter A; Habuchi T; Knowles MA
Br J Cancer; 1999 May; 80(5-6):904-8. PubMed ID: 10360673
[TBL] [Abstract][Full Text] [Related]
18. Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome.
Allory Y; Beukers W; Sagrera A; Flández M; Marqués M; Márquez M; van der Keur KA; Dyrskjot L; Lurkin I; Vermeij M; Carrato A; Lloreta J; Lorente JA; Carrillo-de Santa Pau E; Masius RG; Kogevinas M; Steyerberg EW; van Tilborg AA; Abas C; Orntoft TF; Zuiverloon TC; Malats N; Zwarthoff EC; Real FX
Eur Urol; 2014 Feb; 65(2):360-6. PubMed ID: 24018021
[TBL] [Abstract][Full Text] [Related]
19. Differential PTEN protein expression profiles in superficial versus invasive bladder cancers.
Koksal IT; Yasar D; Dirice E; Usta MF; Karauzum S; Luleci G; Baykara M; Sanlioglu S
Urol Int; 2005; 75(2):102-6. PubMed ID: 16123561
[TBL] [Abstract][Full Text] [Related]
20. p53 expression compared with other prognostic factors in OMS grade-I stage-Ta transitional cell carcinoma of the bladder.
Casetta G; Gontero P; Russo R; Pacchioni D; Tizzani A
Eur Urol; 1997; 32(2):229-36. PubMed ID: 9286659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
